Generation bio announces demonstration of highly selective t cell transduction in vivo with cell-targeted lnp platform

Cambridge, mass., oct. 26, 2023 (globe newswire) -- generation bio co. (nasdaq:gbio), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that it has reached two significant achievements through in vivo studies, including results generated as part of its collaboration with moderna, inc. first, generation bio has shown highly selective t cell targeting in vivo with its cell-targeted lnp (ctlnp) platform in a humanized mouse model. separately, the company has confirmed the stealth properties of its ctlnp platform in non-human primates (nhps). generation bio will present these data at the european society for gene and cell therapy (esgct) 30th annual congress in brussels, belgium at 4:40 p.m. cest today. slides from the presentation will be made available on generation bio's website following the presentation.
GBIO Ratings Summary
GBIO Quant Ranking